Comparing the GORE VIABAHN VBX Balloon Expandable Endoprosthesis to Bare Metal Stents for Treating Complex Iliac Artery Blockages
Led by W.L.Gore & Associates · Updated on 2026-05-13
244
Participants Needed
43
Research Sites
200 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a device called the GORE VIABAHN VBX Balloon Expandable Endoprosthesis to treat people with complex iliac occlusive disease, a condition affecting blood flow in the iliac arteries. This clinical trial is designed to compare this device to bare metal stenting, aiming to see which approach better keeps the arteries open over time. The study is prospective, multicenter, randomized, and controlled with a double masking design.
Participants will be randomly assigned to one of two groups one receiving the GORE VIABAHN VBX device and the other receiving a commercially available bare metal stent approved for this condition. Treatments focus on the common andor external iliac arteries with lesions between 4 and 11 cm and vessel diameters between 5 mm and 13 mm. Both groups will receive stenting procedures using these devices.
During the trial, participants will undergo evaluations to measure artery openness primary patency at one year and up to five years. Additional measures include technical and clinical success of procedures, hemodynamic status, quality of life changes, freedom from restenosis and revascularization, amputation-free survival, and overall survival. The study involves follow-up visits over several years to monitor these outcomes and safety.
CONDITIONS
Brief Title
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
Research Team
A
Alexander Ambrocik
E
Enoque Costa
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
GORE® VIABAHN® VBX Covered Stent Graft
Bare‑Metal Stent (BMS)
What it is
A balloon‑expandable covered stent graft (GORE® VIABAHN® VBX) placed in complex iliac artery occlusive lesions
A commercially available bare‑metal stent approved for iliac artery occlusive disease
Role in trial
Investigational device arm tested for superiority in primary patency
Active control arm using a standard bare‑metal stent
Primary use
To maintain vessel patency in complex iliac occlusive disease
To maintain vessel patency in complex iliac occlusive disease
How it is given or performed
Endovascular placement of a balloon‑expandable covered stent in iliac artery lesions
Endovascular placement of a bare‑metal stent in iliac artery lesions
Evidence status
Covered stents in aortoiliac disease show better primary patency and lower reintervention than bare‑metal stents in meta‑analysis
Bare‑metal stents are standard but associated with lower patency in complex lesions compared to covered stents
Important limitations
Long‑term outcomes beyond five years are not yet available
Lower long‑term patency in complex iliac lesions based on prior data
Patient impact
May achieve longer vessel openness and reduce need for repeat procedure in complex lesions
Less durable performance may result in more repeat procedures in complex lesions
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older at time of informed consent
Signed informed consent form
Ability to comply with protocol requirements including follow-up
Symptoms of claudication, rest pain, or minor tissue loss (Rutherford Category 2-5)
De novo or restenotic lesion(s) in the common and/or external iliac artery(ies)
Unilateral or bilateral lesions (>50% stenosis or chronic total occlusion) each 4 to 11 cm in length
Target vessel diameter approximately between 5 mm and 13 mm
Sufficient common femoral artery and at least one femoral artery (<50% stenotic)
At least one sufficient infrapopliteal run-off vessel (<50% stenotic)
You will not qualify if you...
Life expectancy less than 1 year
Pregnancy at time of informed consent
Known allergy to stent or stent graft materials including nitinol, stainless steel, or heparin
Severe chronic renal insufficiency (serum creatinine > 2.5 mg/dL) without hemodialysis
Evidence of systemic infection
Known intolerance to antithrombotic medications preventing compliance
Vascular catheterization of lower extremities within 30 days prior to randomization (except diagnostic angiograms for study)
Previous stenting in the iliac arteries
Previous surgical bypass in the target limb
Participation in another investigative clinical study without sponsor approval
Lesion requiring drug-coated balloon angioplasty, atherectomy, lithotripsy, or ablative device for stent delivery
Presence of abdominal aortic artery lesion or aneurysm
Lesion requiring stent placement within 2 cm of the inguinal ligament
Isolated common iliac artery stenosis treatable with a single device without kissing stents or extension into external iliac artery
Outflow disease requiring additional interventions such as common femoral endarterectomy or femoral/tibial revascularization
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Implementation
Duration - Procedure day
Participants receive stenting treatment of the common and/or external iliac arteries using either the GORE VIABAHN VBX Balloon Expandable Endoprosthesis or a commercially available bare metal stent.
1 procedure visit (in-person)
Long-term Monitoring
Duration - Up to 5 years
Participants are monitored for clinical success, hemodynamic status, patency, and other outcomes through 5 years after treatment.
Periodic follow-up visits over 5 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Safety and Effectiveness Study of Renzan Peripheral Stent in Treating Femoro-Popliteal Artery Disease in Tuscany
Real-World Observational Registry Tracking Chronic Wounds and Ulcers Across All Ages and Care Settings
Evaluation of the Long >150mm Passeo-18 Lux Drug-Coated Balloon for Treating Infrainguinal Artery Blockages in Lower Leg Arteries
Phase 2a Study of SRSD107 Given by Injection in Adults With Chronic Coronary or Peripheral Arterial Disease
Evaluating Sperstent and Everflex Stent Systems for Treating Residual Lesions in Femoropopliteal Arteries After Balloon Angioplasty
Physical Activity Program to Improve Walking and Quality of Life in Adults with Lower Limb Peripheral Arterial Disease
Registry to Assess Safety and Performance of Atrium Advanta VXT and Flixene Vascular Grafts in Peripheral Artery Repair or Replacement
Study of How Fitness, Oral Bacteria, and Blood Flow to Muscles Are Connected
Including People With and Without Heart Failure or Peripheral Artery Disease
Using Contrast Ultrasound to Improve Blood Flow in Limbs for Adults With or Without Peripheral Arterial Disease
Clinical Survey of the Medtronic Liberant Thrombectomy System
for Removing Blood Clots in Peripheral Arteries and Veins
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
FORWARD Study of GORE VIABAHN Balloon-Expandable Endoprostheses and Bare Metal Stents in the United States, European Union, United Kingdom, Australia, and New Zealand When Placed to Treat Complex Iliac Occlusive Disease: Protocol for a Randomized Superiority Trial.
Melissa L Kirkwood, Ehrin J Armstrong, Mohammad M Ansari...